Edition:
United Kingdom

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

4.08EUR
9:34am BST
Change (% chg)

€0.00 (+0.00%)
Prev Close
€4.08
Open
€4.08
Day's High
€4.10
Day's Low
€4.08
Volume
5,585
Avg. Vol
76,028
52-wk High
€11.15
52-wk Low
€4.05

Latest Key Developments (Source: Significant Developments)

-AB Science Reports Positive Idmc Recommendation To Continue Study Based On A Trend Analysis Of Study In Refractory Metastatic Colorectal Cancer
Monday, 23 Jul 2018 

July 23 (Reuters) - AB Science SA ::REG-AB SCIENCE REPORTS POSITIVE IDMC RECOMMENDATION TO CONTINUE THE STUDY BASED ON A TREND ANALYSIS OF THE MASITINIB PHASE 2/3 STUDY IN REFRACTORY METASTATIC COLORECTAL CANCER.STUDY'S PRIMARY ENDPOINT IS OVERALL SURVIVAL (OS).EXPECTS STUDY AB12010 TO BE COMPLETED IN 2019.SAYS A TREND ANALYSIS FOR OS WAS PLANNED AFTER A CERTAIN NUMBER OF EVENTS ARE OBSERVED.INTERIM ANALYSIS IS PLANNED AFTER AROUND 50% OF TOTAL NUMBER OF REQUIRED EVENTS.  Full Article

AB Science FY Operating Loss Down At 28.4 Million Euros
Monday, 30 Apr 2018 

April 30 (Reuters) - AB SCIENCE SA ::FY NET LOSS EUR 27.1 MILLION VERSUS LOSS OF EUR 27.7 MILLION YEAR AGO.AB SCIENCE REPORTS TODAY ITS ANNUAL FINANCIALS AS OF 31 DECEMBER 2017 AND PROVIDES AN UPDATE ON ITS ACTIVITIES.FY NET REVENUES EUR 1.7 MILLION VERSUS EUR 1.5 MILLION YEAR AGO.FY OPERATING LOSS EUR 28.4 MILLION VERSUS LOSS OF EUR 30.2 MILLION YEAR AGO.INTENDS TO LAUNCH BY END 2018 A PHASE 1/2 REFRACTORY ACUTE MYELOID LEUKEMIA STUDY WITH NEW MOLECULE.INTENDS TO LAUNCH A CONFIRMATORY PHASE 3 STUDY IN INDOLENT SYSTEMIC MASTOCYTOSIS.SUBJECT TO AVAILABILITY OF FINANCIAL RESOURCES, AIMS TO START IN 2018 PRECLINICAL STUDIES OF NEW MOLECULES.  Full Article

AB Science Announces Negative Opinion From CHMP
Thursday, 19 Apr 2018 

April 19 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT THE CHMP HAS ADOPTED A NEGATIVE OPINION FOR THE MARKETING AUTHORIZATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS.AB SCIENCE WILL PROVIDE ADDITIONAL DATA THROUGH A REEXAMINATION PROCEDURE.RE-EXAMINATION WILL LEAD CHMP TO DELIVER A SECOND OPINION IN JULY 2018.REAFFIRMS ITS COMMITMENT TO CARRY OUT DEVELOPMENT OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS.  Full Article

Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE.‍FINAL RESULTS OF STUDY ARE EXPECTED IN Q2 2019​.‍IDMC DID NOT REPORT ANY SAFETY CONCERN WITH MASITINIB IN STUDY POPULATION​.  Full Article

AB Science: CHMP adopts negative opinion for Masitinib marketing authorization
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT CHMP ADOPTED A NEGATIVE OPINION FOR MASITINIB MARKETING AUTHORIZATION IN INDOLENT SYSTEMIC MASTOCYTOSIS AFTER REASSESSMENT.CHMP CONSIDERED THAT THERE WERE TOO MANY UNCERTAINTIES THAT PRECLUDED THE BENEFIT-RISK ASSESSMENT‍​.TO CONFIRM FIRST STUDY RESULTS WITH CONFIRMATORY STUDY IN MASTOCYTOSIS PATIENTS UNRESPONSIVE TO SYMPTOMATIC TREATMENT.  Full Article

BRIEF-AB Science FY Operating Loss Down At 28.4 Million Euros

* FY NET LOSS EUR 27.1 MILLION VERSUS LOSS OF EUR 27.7 MILLION YEAR AGO